文献速递肿瘤 PET/CT核素与放射性配体治疗

基于临床数据与乳腺[18F]FDG-PET/MRI影像数据的机器学习预测乳腺癌患者治疗反应

Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [18F]FDG-PET/MRI.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-12-22

该研究回顾性纳入143例新诊断乳腺癌女性,利用基线乳腺[18F]FDG-PET/MRI及临床数据构建XGBoost模型预测新辅助系统治疗后的病理完全缓解。嵌套交叉验证显示平均ROC-AUC为80.4±6.0%,但作者认为性能尚不足以用于临床决策。

要点

  • XGBoost模型预测pCR的平均ROC-AUC为80.4±6.0%。
  • 组织病理学特征对分类贡献最大,其次为PET、MRI和社会人口学/人体测量学特征。
  • 作者认为模型性能尚不足以纳入临床决策过程。

核心结论

  • 多源XGBoost模型在预测乳腺癌患者NAST前pCR方面显示出有希望的结果,但所得性能尚不足以应用于临床决策过程。

研究设计与样本

  • 回顾性纳入143例新诊断乳腺癌女性(54±12岁),均接受乳腺[18F]FDG-PET/MRI、肿瘤病灶组织病理学检查及临床数据评估。
  • 生成56个来自PET、MRI、社会人口学/人体测量学、组织病理学及临床数据的特征,作为极端梯度提升模型(XGBoost)的输入以预测pCR。
  • 模型在五折嵌套交叉验证中评估,内层循环包含独立超参数调优以降低过度乐观估计的风险。

主要发现

  • 嵌套交叉验证预测pCR的平均ROC-AUC为80.4±6.0%。
  • 平均灵敏度、特异度、PPV和NPV分别为54.5±21.3%、83.6±4.2%、63.6±8.5%和77.6±8.1%。
  • 组织病理学数据是XGBoost模型分类最重要的特征,其次为PET、MRI和社会人口学/人体测量学特征。

关键数值与推荐

  • 诊断模型性能通过ROC-AUC、灵敏度、特异度、PPV、NPV和准确率评估。
  • XGBoost模型特征重要性评估用于判断哪些特征对区分pCR与非pCR贡献最大。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出所得性能尚不足以应用于临床决策过程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate if a machine learning prediction model based on clinical and easily assessable imaging features derived from baseline breast [18F]FDG-PET/MRI staging can predict pathologic complete response (pCR) in patients with newly diagnosed breast cancer prior to neoadjuvant system therapy (NAST). METHODS: Altogether 143 women with newly diagnosed breast cancer (54 ± 12 years) were retrospectively enrolled. All women underwent a breast [18F]FDG-PET/MRI, a histopathological workup of their breast cancer lesions and evaluation of clinical data. Fifty-six features derived from positron emission tomography (PET), magnetic resonance imaging (MRI), sociodemographic / anthropometric, histopathologic as well as clinical data were generated and used as input for an extreme Gradient Boosting model (XGBoost) to predict pCR. The model was evaluated in a five-fold nested-cross-validation incorporating independent hyper-parameter tuning within the inner loops to reduce the risk of overoptimistic estimations. Diagnostic model-performance was assessed by determining the area under the curve of the receiver operating characteristics curve (ROC-AUC), sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Furthermore, feature importances of the XGBoost model were evaluated to assess which features contributed most to distinguish between pCR and non-pCR. RESULTS: Nested-cross-validation yielded a mean ROC-AUC of 80.4 ± 6.0% for prediction of pCR. Mean sensitivity, specificity, PPV, and NPV of 54.5 ± 21.3%, 83.6 ± 4.2%, 63.6 ± 8.5%, and 77.6 ± 8.1% could be achieved. Histopathological data were the most important features for classification of the XGBoost model followed by PET, MRI, and sociodemographic/anthropometric features. CONCLUSION: The evaluated multi-source XGBoost model shows promising results for reliably predicting pathological complete response in breast cancer patients prior to NAST. However, yielded performance is yet insufficient to be implemented in the clinical decision-making process.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Jannusch K, Dietzel F, Bruckmann NM, et al. Prediction of therapy response of breast cancer patients with machine learning based on clinical data and imaging data derived from breast [18F]FDG-PET/MRI. Eur J Nucl Med Mol Imaging. 2023. PMID: 38133687. doi:10.1007/s00259-023-06513-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。